These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 19040555)

  • 1. The pharmacology of lysergic acid diethylamide: a review.
    Passie T; Halpern JH; Stichtenoth DO; Emrich HM; Hintzen A
    CNS Neurosci Ther; 2008; 14(4):295-314. PubMed ID: 19040555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
    Nichols DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2331-2343. PubMed ID: 29461039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LSD before Leary. Sidney Cohen's critique of 1950s psychedelic drug research.
    Novak SJ
    Isis; 1997 Mar; 88(1):87-110. PubMed ID: 9154737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
    Liester MB
    Curr Drug Abuse Rev; 2014; 7(3):146-56. PubMed ID: 25563445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
    Pouyan N; Younesi Sisi F; Kargar A; Scheidegger M; McIntyre RS; Morrow JD
    CNS Drugs; 2023 Dec; 37(12):1027-1063. PubMed ID: 37999867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei.
    Larson AA; Chinn C; Proudfit HK; Anderson EG
    J Pharmacol Exp Ther; 1981 Apr; 217(1):99-104. PubMed ID: 6110778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution.
    Tagliazucchi E; Roseman L; Kaelen M; Orban C; Muthukumaraswamy SD; Murphy K; Laufs H; Leech R; McGonigle J; Crossley N; Bullmore E; Williams T; Bolstridge M; Feilding A; Nutt DJ; Carhart-Harris R
    Curr Biol; 2016 Apr; 26(8):1043-50. PubMed ID: 27085214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
    Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20
    Aday JS; Bloesch EK; Davoli CC
    J Psychoactive Drugs; 2019; 51(3):210-217. PubMed ID: 30836890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
    Hungen KV; Roberts S; Hill DF
    Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of lysergic acid diethylamide (LSD): an update.
    Libânio Osório Marta RF
    Drug Metab Rev; 2019 Aug; 51(3):378-387. PubMed ID: 31266388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.
    Burris KD; Breeding M; Sanders-Bush E
    J Pharmacol Exp Ther; 1991 Sep; 258(3):891-6. PubMed ID: 1679849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
    Burris KD; Sanders-Bush E
    Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
    De Gregorio D; Comai S; Posa L; Gobbi G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats.
    Popik P; Krawczyk M; Kuziak A; Bugno R; Hogendorf A; Staroń J; Nikiforuk A
    J Psychopharmacol; 2019 Nov; 33(11):1447-1455. PubMed ID: 31452444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argyreia nervosa (Burm. f.): receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches.
    Paulke A; Kremer C; Wunder C; Achenbach J; Djahanschiri B; Elias A; Schwed JS; Hübner H; Gmeiner P; Proschak E; Toennes SW; Stark H
    J Ethnopharmacol; 2013 Jul; 148(2):492-7. PubMed ID: 23665164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The paradoxical psychological effects of lysergic acid diethylamide (LSD).
    Carhart-Harris RL; Kaelen M; Bolstridge M; Williams TM; Williams LT; Underwood R; Feilding A; Nutt DJ
    Psychol Med; 2016 May; 46(7):1379-90. PubMed ID: 26847689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
    Buckholtz NS; Zhou DF; Freedman DX; Potter WZ
    Neuropsychopharmacology; 1990 Apr; 3(2):137-48. PubMed ID: 1969270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
    Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
    J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.